Publicaciones en las que colabora con Juan Berenguer Berenguer (29)

2024

  1. Plasma metabolomic profile is near-normal in people with HIV on long-term suppressive antiretroviral therapy

    Frontiers in Cellular and Infection Microbiology, Vol. 14

2023

  1. Corrigendum to “PBMCs gene expression signature of advanced cirrhosis with high risk for clinically significant portal hypertension in HIV/HCV coinfected patients: A cross-control study” [Biomed. Pharmacother. 159 (2023) 114220] (Biomedicine & Pharmacotherapy (2023) 159, (S0753332223000082), (10.1016/j.biopha.2023.114220))

    Biomedicine and Pharmacotherapy

  2. PBMCs gene expression signature of advanced cirrhosis with high risk for clinically significant portal hypertension in HIV/HCV coinfected patients: A cross-control study

    Biomedicine and Pharmacotherapy, Vol. 159

  3. Predictive plasma biomarkers of long-term increase in hepatic steatosis index after HCV eradication in HIV/HCV-coinfected patients

    Biomedicine and Pharmacotherapy, Vol. 164

2022

  1. Blood microbiome is associated with changes in portal hypertension after successful direct-acting antiviral therapy in patients with HCV-related cirrhosis

    The Journal of antimicrobial chemotherapy, Vol. 77, Núm. 3, pp. 719-726

  2. Discovering HIV related information by means of association rules and machine learning

    Scientific Reports, Vol. 12, Núm. 1

  3. Metabolomic changes after DAAs therapy are related to the improvement of cirrhosis and inflammation in HIV/HCV-coinfected patients

    Biomedicine and Pharmacotherapy, Vol. 147

  4. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort

    HIV Medicine, Vol. 23, Núm. 8, pp. 825-836

  5. Similar humoral immune responses against the SARS-CoV-2 spike protein in HIV and non-HIV individuals after COVID-19

    Journal of Infection

2021

  1. COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study

    HIV Medicine, Vol. 22, Núm. 9, pp. 867-876

  2. HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients

    Frontiers in Immunology, Vol. 12

  3. HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients

    Journal of Biomedical Science, Vol. 28, Núm. 1

2020

  1. Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain

    Clinical Microbiology and Infection, Vol. 26, Núm. 11, pp. 1525-1536

  2. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study

    The Lancet HIV, Vol. 7, Núm. 8, pp. e565-e573

  3. How well are we performing the initial assessment of HIV-positive patients? Results from a multicentre cohort in Spain

    HIV Medicine, Vol. 21, Núm. 2, pp. 128-134

  4. Plasma metabolomic fingerprint of advanced cirrhosis stages among HIV/HCV-coinfected and HCV-monoinfected patients

    Liver International, Vol. 40, Núm. 9, pp. 2215-2227

  5. Telomere length increase in HIV/HCV-coinfected patients with cirrhosis after HCV eradication with direct-acting antivirals

    Journal of Clinical Medicine, Vol. 9, Núm. 8, pp. 1-13

  6. Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Genetic variants upstream of TNFAIP3 in the 6q23 region are associated with liver disease severity in HIV/HCV-coinfected patients: A cross-sectional study

    Infection, Genetics and Evolution, Vol. 67, pp. 112-120

2017

  1. ADAR1 polymorphisms are related to severity of liver fibrosis in HIV/HCV-coinfected patients

    Scientific Reports, Vol. 7, Núm. 1